WO2008106202A1 - Modulateurs de théramutéine - Google Patents
Modulateurs de théramutéine Download PDFInfo
- Publication number
- WO2008106202A1 WO2008106202A1 PCT/US2008/002656 US2008002656W WO2008106202A1 WO 2008106202 A1 WO2008106202 A1 WO 2008106202A1 US 2008002656 W US2008002656 W US 2008002656W WO 2008106202 A1 WO2008106202 A1 WO 2008106202A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- alkyl
- aryl
- aralkyl
- membered
- Prior art date
Links
- 0 C(C1)C2C[C@@]1*C2 Chemical compound C(C1)C2C[C@@]1*C2 0.000 description 9
- PSGCKFMXUCKHDI-UHFFFAOYSA-N CN(C(C=C1)c2nc(-c(nc3N4CCOCC4)ncc3F)ncc2)C=C1Nc1cccc(C(F)(F)F)c1 Chemical compound CN(C(C=C1)c2nc(-c(nc3N4CCOCC4)ncc3F)ncc2)C=C1Nc1cccc(C(F)(F)F)c1 PSGCKFMXUCKHDI-UHFFFAOYSA-N 0.000 description 1
- QBSCRFVWIMSLCD-CMDGGOBGSA-N CN(C)/C=C/C(c(cc1)ncc1Nc1cc(C(F)(F)F)ccc1)=O Chemical compound CN(C)/C=C/C(c(cc1)ncc1Nc1cc(C(F)(F)F)ccc1)=O QBSCRFVWIMSLCD-CMDGGOBGSA-N 0.000 description 1
- RLYUNPNLXMSXAX-UHFFFAOYSA-N Cc1cnc[s]1 Chemical compound Cc1cnc[s]1 RLYUNPNLXMSXAX-UHFFFAOYSA-N 0.000 description 1
- FCYAEBKYBSIJME-UHFFFAOYSA-N FC(c1cc(Nc(cc2)cnc2-c2nc(-c(nc3N4CCOCC4)ncc3F)ncc2)ccc1)(F)F Chemical compound FC(c1cc(Nc(cc2)cnc2-c2nc(-c(nc3N4CCOCC4)ncc3F)ncc2)ccc1)(F)F FCYAEBKYBSIJME-UHFFFAOYSA-N 0.000 description 1
- YQBWTAQJHPOYJM-UHFFFAOYSA-N NC(c(nc1)nc(N2CCOCC2)c1F)=N Chemical compound NC(c(nc1)nc(N2CCOCC2)c1F)=N YQBWTAQJHPOYJM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des agents qui sont des inhibiteurs ou des activateurs de formes variantes de protéines endogènes et de nouveaux procédés d'identification de telles variantes. Des inhibiteurs et des activateurs de variantes de protéine endogène, codés par des gènes qui ont muté, sont d'un intérêt particulier, lesquelles variantes apparaissent souvent ou sont au moins tout d'abord identifiées comme étant apparues à la suite d'une exposition à un agent chimique qui est connu pour être un inhibiteur ou un activateur de la protéine endogène non mutée correspondante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90411507P | 2007-02-27 | 2007-02-27 | |
US60/904,115 | 2007-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008106202A1 true WO2008106202A1 (fr) | 2008-09-04 |
Family
ID=39721555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/002656 WO2008106202A1 (fr) | 2007-02-27 | 2008-02-27 | Modulateurs de théramutéine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008106202A1 (fr) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010098866A1 (fr) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
US8796310B2 (en) | 2011-05-04 | 2014-08-05 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8987461B2 (en) | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
JP2018504449A (ja) * | 2015-02-04 | 2018-02-15 | ビヨンドバイオ インコーポレイテッド | ヘテロ環化合物及びそれを含む薬剤学的組成物 |
US10039761B2 (en) | 2013-10-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10875848B2 (en) | 2018-10-10 | 2020-12-29 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (FASN) |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2021035788A1 (fr) * | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | Dérivé de pyrazole et son utilisation |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041102A1 (fr) * | 1996-05-01 | 1997-11-06 | Ortho Pharmaceutical Corporation | Derives carboxamide de pyrrolidine, piperidine et hexahydroazepine utilises dans le traitement de troubles thrombotiques |
WO2005115992A1 (fr) * | 2004-05-23 | 2005-12-08 | Housey Pharmaceuticals, Inc. | Modulateurs de theramuteine |
WO2006047631A2 (fr) * | 2004-10-25 | 2006-05-04 | University Of Medicine And Dentistry Of New Jersey | Composes antimitotiques antiproliferatifs |
-
2008
- 2008-02-27 WO PCT/US2008/002656 patent/WO2008106202A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041102A1 (fr) * | 1996-05-01 | 1997-11-06 | Ortho Pharmaceutical Corporation | Derives carboxamide de pyrrolidine, piperidine et hexahydroazepine utilises dans le traitement de troubles thrombotiques |
WO2005115992A1 (fr) * | 2004-05-23 | 2005-12-08 | Housey Pharmaceuticals, Inc. | Modulateurs de theramuteine |
WO2006047631A2 (fr) * | 2004-10-25 | 2006-05-04 | University Of Medicine And Dentistry Of New Jersey | Composes antimitotiques antiproliferatifs |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
US8822518B2 (en) | 2006-08-09 | 2014-09-02 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
WO2010098866A1 (fr) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase |
US8796310B2 (en) | 2011-05-04 | 2014-08-05 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors |
US9592232B2 (en) | 2012-04-24 | 2017-03-14 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10076521B2 (en) | 2012-04-24 | 2018-09-18 | Vertex Pharamceuticals Incorporated | DNA-PK inhibitors |
US9925188B2 (en) | 2012-04-24 | 2018-03-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors and uses thereof |
US11021465B2 (en) | 2012-04-24 | 2021-06-01 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10501439B2 (en) | 2012-04-24 | 2019-12-10 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9376448B2 (en) | 2012-04-24 | 2016-06-28 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US11008305B2 (en) | 2012-04-24 | 2021-05-18 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9296701B2 (en) | 2012-04-24 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10442791B2 (en) | 2012-04-24 | 2019-10-15 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9878993B2 (en) | 2012-04-24 | 2018-01-30 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors for treatment of cancer |
US10391095B2 (en) | 2012-04-24 | 2019-08-27 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9458129B2 (en) | 2012-12-06 | 2016-10-04 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US8987461B2 (en) | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
US9107916B2 (en) | 2012-12-06 | 2015-08-18 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
US9908865B2 (en) | 2012-12-06 | 2018-03-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US10173996B2 (en) | 2012-12-06 | 2019-01-08 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US9604961B2 (en) | 2012-12-06 | 2017-03-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US9714230B2 (en) | 2012-12-06 | 2017-07-25 | Celgene Quantical Research, Inc. | Histone demethylase inhibitors |
US11813267B2 (en) | 2013-03-12 | 2023-11-14 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10258627B2 (en) | 2013-03-12 | 2019-04-16 | Vertex Pharmaceutical Incorporated | DNA-PK inhibitors |
US9987284B2 (en) | 2013-03-12 | 2018-06-05 | Vertex Pharmaceuticals Incorporated | Substituted benzooxadiazole DNA-PK inhibitors |
US9359380B2 (en) | 2013-03-12 | 2016-06-07 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US9340557B2 (en) | 2013-03-12 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US10786512B2 (en) | 2013-03-12 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
US10973830B2 (en) | 2013-03-12 | 2021-04-13 | Vertex Pharmaceuticals Incorporated | Substituted quinoxaline DNA-PK inhibitors |
US10716789B2 (en) | 2013-10-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10039761B2 (en) | 2013-10-17 | 2018-08-07 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
JP2018504449A (ja) * | 2015-02-04 | 2018-02-15 | ビヨンドバイオ インコーポレイテッド | ヘテロ環化合物及びそれを含む薬剤学的組成物 |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
US10710986B2 (en) | 2018-02-13 | 2020-07-14 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11555029B2 (en) | 2018-02-13 | 2023-01-17 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10774071B2 (en) | 2018-07-13 | 2020-09-15 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10875848B2 (en) | 2018-10-10 | 2020-12-29 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (FASN) |
US11299484B2 (en) | 2018-10-10 | 2022-04-12 | Forma Therapeutics, Inc. | Inhibiting fatty acid synthase (FASN) |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
WO2021035788A1 (fr) * | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | Dérivé de pyrazole et son utilisation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008106202A1 (fr) | Modulateurs de théramutéine | |
US11491164B2 (en) | Theramutein modulators | |
WO2008091681A2 (fr) | Modulateurs des théramutéines | |
US20100016298A1 (en) | Theramutein modulators | |
US11714080B2 (en) | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | |
WO2007062213A2 (fr) | Composes et procedes d’identification, de synthese, d’optimisation et de creation de profils de modulateurs de proteines | |
US20090275070A1 (en) | Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | |
AU2012203664B2 (en) | Theramutein modulators | |
Class et al. | Patent application title: Compounds and Method of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators Inventors: Gerard M. Housefly (Southfield, MI, US) Gerard M. Housefly (Southfield, MI, US) Hmi Medical Innovations, Llc. Assignees: HMI MEDICAL INNOVATIONS, LLC. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08726229 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08726229 Country of ref document: EP Kind code of ref document: A1 |